간세포암 치료제 시장 규모, 점유율, 성장 분석 : 약제 클래스별, 요법 유형별, 치료 유형별, 투여 경로별, 최종사용자별, 유통 채널별, 지역별 - 산업 예측(2025-2032년)
Hepatocellular Carcinoma Drugs Market Size, Share, and Growth Analysis, By Drug Class, By Therapy Type, By Treatment Type, By Route of Administration, By End-Users, By Distribution Channel, By Region - Industry Forecast 2025-2032
상품코드:1764754
리서치사:SkyQuest
발행일:2025년 07월
페이지 정보:영문 198 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 간세포암 치료제 시장 규모는 2023년에 14억 달러로 평가되며, 예측 기간(2025-2032년)에 CAGR 8.3%로 성장하며, 2024년 15억 2,000만 달러에서 2032년에는 28억 7,000만 달러로 성장할 전망입니다.
세계 간세포암(HCC) 치료제 시장은 환자 인구 통계학적 변화, 종양학에 대한 정부 지출 증가, 표적 치료의 발전 등으로 인해 큰 성장을 보이고 있습니다. 의료 기술 혁신에 대한 전 세계적인 투자로 인해 새로운 치료법, 특히 간암에 특화된 정밀의료의 도입이 가속화되고 있습니다. 조기 진단 증가, 면역요법 및 병용요법의 도입 증가와 함께 의료 서비스 제공 시스템 전반에 걸쳐 간세포암 치료제의 사용이 확대되고 있습니다. 바이오마커 유도 치료와 차세대 티로신 키나아제 억제제(TKI)와 같은 정밀 종양학 분야의 주목할 만한 기술 혁신은 간세포암 치료의 돌파구를 마련하고 있습니다. 또한 인공지능을 활용한 신약개발 플랫폼은 유망한 신규 면역치료제의 신속한 개발을 촉진하여 시장의 잠재력을 더욱 높이고 있습니다.
목차
서론
조사의 목적
조사 범위
정의
조사 방법
정보 조달
2차와 1차 데이터 방법
시장 규모 예측
시장의 전제조건과 제한
개요
세계 시장 전망
공급과 수요 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
촉진요인과 기회
억제요인과 과제
Porter의 산업 분석
주요 시장 인사이트
주요 성공 요인
경쟁의 정도
주요 투자 기회
시장 에코시스템
시장의 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
사례 연구
간세포암 치료제 시장 규모 : 약제 클래스별 & CAGR(2025-2032년)
시장 개요
PD-1/PD-L1저해제
티로신 키나아제 저해제
간세포암 치료제 시장 규모 : 요법 유형별 & CAGR(2025-2032년)
시장 개요
표적치료
면역치료
기타
간세포암 치료제 시장 규모 : 치료 유형별 & CAGR(2025-2032년)
시장 개요
약물 요법, 수술
방사선 요법
화학요법
기타
간세포암 치료제 시장 규모 : 투여 경로별 & CAGR(2025-2032년)
시장 개요
경구
주사제
기타
간세포암 치료제 시장 규모 : 최종사용자별 & CAGR(2025-2032년)
시장 개요
병원
홈케어
전문 클리닉
기타
간세포암 치료제 시장 규모 : 유통 채널별 & CAGR(2025-2032년)
시장 개요
병원 약국
온라인 약국
소매 약국
간세포암 치료제 시장 규모 : 지역별 & CAGR(2025-2032년)
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽 지역
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카 지역
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
상위 5사의 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채택한 전략
최근 시장 동향
기업의 시장 점유율 분석(2024년)
주요 기업의 기업 개요
기업의 상세
제품 포트폴리오 분석
기업의 부문별 점유율 분석
매출의 전년대비 비교(2022-2024년)
주요 기업 개요
Exelixis, Inc.(US)
Merck & Co., Inc.(US)
AstraZeneca(UK)
Bristol-Myers Squibb Company(US)
Eli Lilly and Company(US)
SillaJen, Inc.(South Korea)
Bayer AG(Germany)
Janssen Global Services, LLC(US)
Pfizer Inc.(US)
F. Hoffmann-La Roche Ltd(Switzerland)
Gilead Sciences, Inc.(US)
GSK plc(UK)
Takeda Pharmaceutical Company Limited(Japan)
Amgen Inc.(US)
Polaris Group(US)
Hepion Pharmaceuticals, Inc.(US)
Provectus Biopharmaceuticals, Inc.(US)
결론과 제안
KSA
영문 목차
영문목차
Global Hepatocellular Carcinoma Drugs Market size was valued at USD 1.4 billion in 2023 and is poised to grow from USD 1.52 billion in 2024 to USD 2.87 billion by 2032, growing at a CAGR of 8.3% during the forecast period (2025-2032).
The global hepatocellular carcinoma (HCC) drugs market is experiencing significant growth, driven by evolving patient demographics, increased government expenditure on oncology, and advancements in targeted therapies. Worldwide investments in health innovation are accelerating the adoption of new treatments, particularly precision medicine dedicated to liver cancer. The rise of early diagnoses, along with the growing implementation of immunotherapies and combination therapies, is expanding the utilization of HCC medications across healthcare delivery systems. Notable innovations in precision oncology, including biomarker-guided therapies and next-generation tyrosine kinase inhibitors (TKIs), are paving the way for breakthroughs in HCC treatment. Additionally, artificial intelligence-driven drug discovery platforms are facilitating the rapid development of promising new immunotherapies, further enhancing the market's prospects.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hepatocellular Carcinoma Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Hepatocellular Carcinoma Drugs Market Segments Analysis
Global Hepatocellular Carcinoma Drugs Market is segmented by Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel and region. Based on Drug Class, the market is segmented into PD-1/PD-L1 Inhibitors and Tyrosine Kinase Inhibitors. Based on Therapy Type, the market is segmented into Targeted Therapy, Immunotherapy and Others. Based on Treatment Type, the market is segmented into Medication, Surgery, Radiotherapy, Chemotherapy and Others. Based on Route of Administration, the market is segmented into Oral, Injectable and Others. Based on End-Users, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Hepatocellular Carcinoma Drugs Market
The global hepatocellular carcinoma (HCC) drugs market is largely driven by the rising incidence of HCC globally, largely due to chronic hepatitis B and C infections that are becoming resistant to treatment. Additionally, increasing alcohol consumption and the prevalence of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH), which are linked to the growing rates of obesity and diabetes, contribute to this upward trend. With a substantial and expanding patient population requiring effective treatment options, there is a consistent demand for both existing therapies and newly developed drugs to address this pressing health challenge.
Restraints in the Global Hepatocellular Carcinoma Drugs Market
The global hepatocellular carcinoma drugs market faces significant obstacles primarily due to the high costs associated with immunotherapies and targeted treatments, which restrict access for patients, particularly in low- and middle-income nations. Additionally, established markets implement stringent health technology assessment (HTA) policies, such as those from NICE and IQWiG, which require lengthy evaluations before providing reimbursement for expensive therapies. This can further limit patient access and delay the introduction of innovative treatments, despite their proven clinical efficacy, thereby hindering the overall growth and development of the market for hepatocellular carcinoma drugs.
Market Trends of the Global Hepatocellular Carcinoma Drugs Market
The Global Hepatocellular Carcinoma (HCC) drug market is witnessing a significant trend towards the rapid expansion of combination therapies, particularly involving PD-1/PD-L1 inhibitors alongside Tyrosine Kinase Inhibitors (TKIs) and anti-angiogenic agents. Notable combinations, such as Roche's Tecentriq (atezolizumab) with Avastin (bevacizumab), have demonstrated remarkable clinical efficacy, including a 42% reduction in mortality risk as observed in the IMbrave150 trial. This trend is further propelled by accelerated approval processes from regulatory bodies like the FDA and EMA, amplifying market growth potential. As clinical outcomes improve, the demand for effective HCC treatments continues to rise, reshaping the landscape of oncological therapies.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies
Global Hepatocellular Carcinoma Drugs Market Size by Drug Class & CAGR (2025-2032)
Market Overview
PD-1/PD-L1 Inhibitors
Tyrosine Kinase Inhibitors
Global Hepatocellular Carcinoma Drugs Market Size by Therapy Type & CAGR (2025-2032)
Market Overview
Targeted Therapy
Immunotherapy
Others
Global Hepatocellular Carcinoma Drugs Market Size by Treatment Type & CAGR (2025-2032)
Market Overview
Medication, Surgery
Radiotherapy
Chemotherapy
Others
Global Hepatocellular Carcinoma Drugs Market Size by Route of Administration & CAGR (2025-2032)
Market Overview
Oral
Injectable
Others
Global Hepatocellular Carcinoma Drugs Market Size by End-Users & CAGR (2025-2032)
Market Overview
Hospitals
Homecare
Specialty Clinics
Others
Global Hepatocellular Carcinoma Drugs Market Size by Distribution Channel & CAGR (2025-2032)
Market Overview
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Global Hepatocellular Carcinoma Drugs Market Size & CAGR (2025-2032)
North America (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
US
Canada
Europe (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
Brazil
Rest of Latin America
Middle East & Africa (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
